PPAR-γ Ligands Repress TGFβ-Induced Myofibroblast Differentiation by Targeting the PI3K/Akt Pathway: Implications for Therapy of Fibrosis
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Transforming growth factor beta (TGFβ) induced differentiation of human lung fibroblasts to myofibroblasts is a key event in the pathogenesis of pulmonary fibrosis. Although the typical TGFβ signaling pathway involves the Smad family of transcription factors, we have previously reported that peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands inhibit TGFβ-mediated differentiation of human lung fibroblasts to myofibroblasts via a Smad-independent pathway. TGFβ also activates the phosphatidylinositol 3 kinase/protein kinase B (PI3K/Akt) pathway leading to phosphorylation of Akt(S473). Here, we report that PPAR-γ ligands, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and 15-deoxy-(12,14)-15d-prostaglandin J(2) (15d-PGJ(2)), inhibit human myofibroblast differentiation of normal and idiopathic pulmonary fibrotic (IPF) fibroblasts, by blocking Akt phosphorylation at Ser473 by a PPAR-γ-independent mechanism. The PI3K inhibitor LY294002 and a dominant-negative inactive kinase-domain mutant of Akt both inhibited TGFβ-stimulated myofibroblast differentiation, as determined by Western blotting for α-smooth muscle actin and calponin. Prostaglandin A(1) (PGA(1)), a structural analogue of 15d-PGJ(2) with an electrophilic center, also reduced TGFβ-driven phosphorylation of Akt, while CAY10410, another analogue that lacks an electrophilic center, did not; implying that the activity of 15d-PGJ(2) and CDDO is dependent on their electrophilic properties. PPAR-γ ligands inhibited TGFβ-induced Akt phosphorylation via both post-translational and post-transcriptional mechanisms. This inhibition is independent of MAPK-p38 and PTEN but is dependent on TGFβ-induced phosphorylation of FAK, a kinase that acts upstream of Akt. Thus, PPAR-γ ligands inhibit TGFβ signaling by affecting two pro-survival pathways that culminate in myofibroblast differentiation. Further studies of PPAR-γ ligands and small electrophilic molecules may lead to a new generation of anti-fibrotic therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 PPAR-γ ligands inhibit TGFβ-induced Akt phosphorylation and myofibroblast differentiation in a PPAR-γ-independent but electrophilic carbon-dependent manner. HLF cells were treated with indicated compounds and/or TGFβ (5ng/ml) for 48 hours. Immunoblots were performed to assess the expression of indicated proteins. Protein lysates from all the indicated samples were electrophoretically separated on the same gel, and representative lanes from a single experiment are shown here. A, the ability of PPAR-γ ligands (CDDO (1µM) and 15d-PGJ2 (5µM)) to reduce p-Akt was not altered upon GW9662-mediated inhibition of PPAR-γ. GW9662 (5µM) inhibits PPAR-γ activity by a covalent bond formation with PPAR-γ protein [36]. R.P. indicates relative changes in Akt phosphorylation compared to control sample, and R.E., relative changes in expression compared to control sample. B, PPAR-γ ligands contain electrophilic carbons. Here, positions of the electrophilic carbons in the structures of the compounds are marked. CAY10410 and PGA1 are structural analogues of 15-d-PGJ2. PGA1 has an electrophilic center but CAY10410 does not. DSPS, like CDDO, has two electrophilic centers. Cells were pre-treated with CAY10410 (5µM), PGA1 (10µM) and DSPS (10µM) for 30 minutes C, only compounds with an electrophilic carbon are able to reduce Akt phosphorylation, indicating that presence of an electrophilic carbon is essential for the observed reduction in the phosphorylation of Akt. All the experiments were performed in triplicate and representative images are shown here.](https://figures.cochat.ai/paper-figures/42fe33a117e847be83731e464fb63bd7/ppar-ligands-repress-tgf-induced-myofibroblast-differentiation-by-targeting-the-figure-3.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overexpression of SMAD3 enhances, whereas knockdown inhibits αSMA and extracellular matrix production in fibroblasts (45–48). Furthermore, fibroblast-specific deletion of SMAD3 reduces αSMA production and myofibroblast phenotype (49–52), for example, loss of SMAD3 lowers the number of activated myofibroblasts in cardiac fibrosis in vivo and reduces extracellular matrix production by myofibroblasts”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006
Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Integrin-regulated FAK–Src signaling in normal and cancer cells
Mitra, S. K., & Schlaepfer, D. D. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.08.011 · Cited by 1,590 · cited 1×
“However, it is widely accepted that integrins are able to activate TGFb [56] and FAK [57,58],”
BackgroundSime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
Self-citationSignaling cross-talk between TGF-β/BMP and other pathways
Guo, X., & Wang, X.-F. (2009) · Cell Research · doi:10.1038/cr.2008.302 · Cited by 1,015 · cited 3×
“Binding of active TGFb to its receptor triggers several signaling pathways [8,9], including the well-characterized Smad pathway and the PI3K/Akt (phosphotidylinositol-3-kinase/Protein Kinase B/PKB) pathway [7,10,11].”
Background15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 1,004
Calalb, M. B., Polte, T. R., & Hanks, S. K. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.2.954 · Cited by 985 · cited 1×
“Increase in phosphorylation of FAK correlates with its increased catalytic activity [20,21] and is required for the recruitment of p85, a regulatory subunit of PI3K [22].”
BackgroundInterleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase
Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., Witztum, J. L., Funk, C. D., Conrad, D., & Glass, C. K. (1999) · Nature · doi:10.1038/22572 · Cited by 855 · cited 1×
“, have shown that PPAR-γ ligands also have effects that are independent of PPAR-γ activity. To examine if inhibition of Akt phosphorylation by PPAR-γ ligands was dependent on the functional activity of PPAR-γ, we used a pharmacological approach involving a PPAR-γ antagonist GW9662, an irreversible PPAR-γ antagonist th…”
Method
Cited by
Items 101–189 of 189
Integrative analyses of genes associated with idiopathic pulmonary fibrosis
Wang, H., Xie, Q., Ou‐Yang, W., & Zhang, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28153 · Cited by 29
“Furthermore, PPAR‐γ ligands are known to repress TGF‐β‐ induced myofibroblast differentiation by targeting the PI3K/Akt pathway in the treatment of fibrosis.(38) Overall, these discoveries are consistent with our data mining results.”
ResultZhao, M., Chen, Y., Ding, G., Xu, Y., Bai, M., Zhang, Y., Jia, Z., Huang, S., & Zhang, A. (2016) · Oncotarget · doi:10.18632/oncotarget.11811 · Cited by 26
“Wei et al found CDDO, a synthetic PPAR-γ agonist, attenuates fibrogenesis by antagonistically targeting canonical TGF-β/Smad and Akt signaling in a PPAR-γ-independent manner [21].”
BackgroundHelal, M. G., & Said, E. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.02.011 · Cited by 24
MicroRNAs regulating signaling pathways in cardiac fibrosis: potential role of the exercise training
Caria, A. C. I., Rodrigues, L. F., Joaquim, V. H. A., Sousa, R. A. L. D., Fernandes, T. M., & de Oliveira, E. M. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00410.2023 · Cited by 25
Kuriyan, A. E., Lehmann, G. M., Kulkarni, A. A., Woeller, C. F., Feldon, S. E., Hindman, H. B., Sime, P. J., Huxlin, K. R., & Phipps, R. P. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.11.018 · Cited by 24
Self-citationLocalization of avβ6 integrin-TGF-β1/Smad3, mTOR and PPARγ in experimental colorectal fibrosis
Latella, G., Vetuschi, A., Sferra, R., Speca, S., & Gaudio, E. (2013) · European Journal of Histochemistry · doi:10.4081/ejh.2013.e40 · Cited by 23
Xie, B., Zheng, G., LI, H., Yao, X., Hong, R., Li, R., WenXiang, Y., & Chen, Y. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4852 · Cited by 22
Mansour, S. M., El-Abhar, H. S., & Soubh, A. A. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00748-w · Cited by 21
Lin, P., Zhang, G., Peng, R., Zhao, M., & Li, H. (2022) · Experimental Dermatology · doi:10.1111/exd.14630 · Cited by 25
Lee, H. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164713 · Cited by 21
He, S., Mengmeng, S., Lan, Z., Fang, Z., & Yu, L.-P. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117308 · Cited by 24
Emerging PPARγ-Independent Role of PPARγLigands in Lung Diseases
Kulkarni, A. A., Woeller, C. F., Thatcher, T. H., Ramon, S., Phipps, R. P., & Sime, P. J. (2012) · PPAR Research · doi:10.1155/2012/705352 · Cited by 24
“Recently, we reported that 15d-PGJ2 and CDDO inhibit TGFβ-induced phosphorylation of phosphotidyl-inositol 3kinase-protein kinase B (PI3K-Akt) and focal adhesion kinase (FAK), but not TGFβ -induced p38-MAPK phosphorylation, and that the mechanism was independent of PPARγ [79].”
BackgroundSelf-citationRamirez, A. M., Ballard, E. N., & Roman, J. (2012) · PPAR Research · doi:10.1155/2012/375876 · Cited by 21
“Furthermore, others have demonstrated protection against TGFβ1-induced myofibroblast transdifferentiation in cells treated with PPARγ activators [12].”
Lacy, S. H., Epa, A. P., Pollock, S. J., Woeller, C. F., Thatcher, T. H., Phipps, R. P., & Sime, P. J. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00565.2016 · Cited by 24
“Likewise, PGD2 and several of its metabolites, including 15d-PGJ2, are known natural ligands for PPAR , a transcription factor that we have previously shown to mediate potent anti-inflammatory and antifibrotic effects in the lung (17, 29, 45).”
Self-citationNanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis
Kanemaru, M., Asai, J., Jo, J., Arita, T., 美奈子, 河., Tsutsumi, M., Wada, M., Tabata, Y., & Katoh, N. (2018) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2018.11.012 · Cited by 23
Lecarpentier, Y., Schussler, O., CLAES, V. A., & Vallée, A. (2017) · Nuclear Receptor Research · doi:10.11131/2017/101299 · Cited by 21
“PPARγ ligands repress TGF-β1-induced myofibroblast differentiation by targeting the PI3K/AKT pathway [115].”
BackgroundInositol possesses antifibrotic activity and mitigates pulmonary fibrosis
Li, J.-M., Chang, W., Li, L., Yang, D. C. H., Hsu, S., Kenyon, N. J., & Chen, C. (2023) · Respiratory Research · doi:10.1186/s12931-023-02421-6 · Cited by 23
Xie, X., Wang, G., Zhang, D., Zhang, Y., Zhu, Y., Li, F., LI, S., & Li, M. (2015) · Biomedical Reports · doi:10.3892/br.2015.465 · Cited by 19
Gao, S., Wu, R., & Zeng, Y. (2011) · Radiation and Environmental Biophysics · doi:10.1007/s00411-011-0390-9 · Cited by 20
“A recent study by Kulkarni et al. (2011) showed that PPAR-c ligands could inhibit TGF-b activity in human lung fibrosis by targeting the PI3K/Akt pathway.”
BackgroundLacy, S. H., Woeller, C. F., Thatcher, T. H., Maddipati, K. R., Honn, K. V., Sime, P. J., & Phipps, R. P. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00272.2016 · Cited by 21
Self-citationClark, S. D., Song, W., Cianciolo, R. E., Lees, G. E., Nabity, M. B., & Liu, S. (2018) · Veterinary Pathology · doi:10.1177/0300985818806050 · Cited by 19
“In addition, PPARa has a number of important downstream effects, including stimulating healthy mitochondrial function, inhibiting NF-kB signaling to promote an anti-inflammatory environment, and inhibiting TGF-b signaling to diminish profibrotic responses.(23,34) ACADM is the gene that encodes for mediumchain acyl-CoA…”
BackgroundRadoslavova, S., Folcher, A., Lefebvre, T., Kondratska, K., Guénin, S., Duthille, I., Gautier, M., Prevarskaya, N. B., & Ouadid‐Ahidouch, H. (2021) · Cancers · doi:10.3390/cancers13102395 · Cited by 22
miR-338-3p blocks TGFβ-induced myofibroblast differentiation through the induction of PTEN
Rackow, A. R., Judge, J., Woeller, C. F., Sime, P. J., & Kottmann, R. M. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00251.2021 · Cited by 19
Self-citationDubey, V., Mishra, A. K., & Ghosh, A. R. (2023) · PPAR Research · doi:10.1155/2023/9458308 · Cited by 19
“Previously, it was shown that PPAR-γ endogenous ligands, 2-cyano-3,12-dioxooleana1,9-dien-28-oic acid and 15d-PGJ(2), can inhibit differentiation of myofibroblast by blocking phosphorylation of Akt (pAkt), and this mechanism was found to be PPAR-γ-independent [27].”
BackgroundAsarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ
Zeng, Q., Zhou, T., Huang, W., Huang, X., Huang, L., Zhang, X., Sang, X., Luo, Y.-Y., Tian, Y., Wu, B., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41933-5 · Cited by 21
Vasaturo, M., Fiengo, L., Tommasi, N. D., Sabatino, L., Ziccardi, P., Colantuoni, V., Bruno, M., Cerchia, C., Novellino, E., Lupo, A., et al. (2017) · Scientific Reports · doi:10.1038/srep41273 · Cited by 17
Li, Z., Wang, S., Qin, Y., Yang, B., Wang, C., Lu, T., Xu, J., Zhu, L., Yuan, C., & Han, W. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176398 · Cited by 20
Byun, K.-A., Lee, J. H., Lee, S. Y., Oh, S., Batsukh, S., Cheon, G. W., Lee, D., Hong, J. H., Son, K. H., & Byun, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137232 · Cited by 23
Calponin Expression in Renal Tubulointerstitial Fibrosis Induced in Rats by Cisplatin
Yuasa, T., Yano, R., Izawa, T., Kuwamura, M., & Yamate, J. (2014) · Journal of Toxicologic Pathology · doi:10.1293/tox.2013-0048 · Cited by 15
Hogan, C. M., Thatcher, T. H., Sapinoro, R., Gurell, M. N., Ferguson, H. E., Pollock, S. J., Jones, C., Phipps, R. P., & Sime, P. J. (2011) · PPAR Research · doi:10.1155/2011/318134 · Cited by 18
“Rosiglitazone, CDDO and 15d-PGJ2 all tightly bind the PPARγ receptor [12, 20, 21], activate PPARγ-dependent transcription [22, 23], and promote adipogenesis via a solely PPARγ-dependent mechanism [12, 25].”
BackgroundSelf-citationLu, Y. Q., Li, A., Lai, X., Jiang, J., Zhang, L., Zhong, Z., Zhao, W., Tang, P., Zhao, H., & Ren, X. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0664-z · Cited by 16
[Retracted] Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis
Kou, L., Kou, P., Luo, G., & Wei, S. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6197219 · Cited by 15
“As mentioned above, TGF-β is a pleiotropic cytokine that binds to receptors to regulate cell proliferation, di ff eren-tiation, and apoptosis, and it plays an important role in ECM synthesis and trauma repair.”
InfluentialRetractedZhang, H., Yang, Y., Cao, Y., & Guan, J. (2024) · Respiratory Research · doi:10.1186/s12931-024-02845-8 · Cited by 19
Zhuang, Y., Li, T., Zhuang, Y., Li, Z., Yang, W., Huang, Q., Li, D., Wu, H., Zhang, G., Yang, T., et al. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.02.005 · Cited by 16
The role of positional information in determining dermal fibroblast diversity
Chitturi, P., & Leask, A. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.02.009 · Cited by 20
Cysteine‐rich protein 1 is regulated by transforming growth factor‐β1 and expressed in lung fibrosis
Järvinen, P. M., Myllärniemi, M., Liu, H., Moore, H. M., Leppäranta, O., Salmenkivi, K., Koli, K. M., Latonen, L., Band, A. M., & Laiho, M. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.23000 · Cited by 15
“Furthermore, peroxisome proliferator-activated receptor-g (PPAR-g) has been shown to repress TGF-binducedmyofibroblast differentiation (Kulkarni et al., 2011) and tumor necrosis factor a (TNF-a) to abrogate TGF-b-induced pulmonary myofibroblast differentiation by inducing early growth response…”
BackgroundTang, X., Wang, C.-N., Zhu, X., & Ni, X. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.013 · Cited by 15
NEDD4-1 and PTEN expression in keloid scarring
Sang, P. F., Wang, H., Wang, M., Hu, C., Zhang, J. S., Li, X. J., & Zhu, F. (2015) · Genetics and Molecular Research · doi:10.4238/2015.october.28.7 · Cited by 14
Kawashima, T., Yamazaki, R., Matsuzawa, Y., Yamaura, E., Takabatake, M., Otake, S., Ikawa, Y., Nakamura, H., Fujino, H., & Murayama, T. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.038 · Cited by 14
Activation of PPAR-γ inhibits PDGF-induced proliferation of mouse renal fibroblasts
Lu, J., Shi, J., Gui, B., Yao, G., Wang, L., Ou, Y., Zhu, D., Ma, L., Ge, H., & Fu, R. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.06.051 · Cited by 13
Kim, J.-E., Park, H., & Kang, T. (2020) · Antioxidants · doi:10.3390/antiox9101026 · Cited by 14
Novel investigational agents for the treatment of scleroderma
McMahan, Z. H., & Wigley, F. M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.848852 · Cited by 13
“PPAR-g PPAR-g inhibits the fibrogenic effects of TGF-b in vitro; agonists of PPAR-g may suppress collagen synthesis, myofibroblast differentiation, and other TGF-b induced fibrotic responses Preclinical [58,59]”
BackgroundZhang, Y. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1966034 · Cited by 12
“Previous data suggested that PPARc plays a key role in anti-fibrotic process by modulating the PI3K/AKT pathway [24].”
BackgroundYe, J., Liu, P., Li, R., Liu, H., Pei, W., Ma, C., Shen, B. Q., Zhao, D., & Chen, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24367 · Cited by 11
Stravodimou, A., Mazzoccoli, G., & Voutsadakis, I. A. (2012) · PPAR Research · doi:10.1155/2012/367450 · Cited by 12
“A reciprocal regulation whence PPARγ agonists inhibit TGFβ signaling is evident in some experimental systems but probably represents a PPARγ-independent effect of these ligands [83, 84].”
Xu, G., Yang, L., Guan, P.-P., Wang, Z., & Wang, P. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00704-1 · Cited by 13
Chhabra, M., & Sharma, S. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.01.036 · Cited by 12
Rubio-Ruiz, M. E., Plata-Corona, J. C., Soria‐Castro, E., Díaz-Juárez, J. A., & Sánchez-Aguilar, M. (2024) · Cells · doi:10.3390/cells13171488 · Cited by 13
“Another example is found in Kulkarni’s work, where the 15 ∆ PGJ2, PPAR gamma endogen ligand inhibits human fibroblast growth by downregulation of TGF-β signaling [15].”
BackgroundCCN2: a bona fide target for anti-fibrotic drug intervention
Leask, A. (2011) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-011-0125-3 · Cited by 11
Anoctamin-1 is induced by TGF-β and contributes to lung myofibroblast differentiation
Reed, E. B., Orbeta, S., Miao, B. A., Sitikov, A. S., Chen, B., Levitan, I., Solway, J., Mutlu, G. M., Fang, Y. H., Mongin, A. A., et al. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00155.2023 · Cited by 12
Jeong, J., & Choi, J. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00257 · Cited by 10
Tan, J., Shen, W., Shi, W., Chen, X., Sun, D., Xu, C., Yan, Q., Cheng, H., Lai, Y., & Ji, H. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.08.012 · Cited by 10
Towards a Unified Approach in Autoimmune Fibrotic Signalling Pathways
Sisto, M., & Lisi, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109060 · Cited by 9
PPARγ Alleviates Right Ventricular Failure Secondary to Pulmonary Arterial Hypertension in Rats
Xu, Y., Gu, Q., Liu, N., Yan, Y., Yang, X., Hao, Y., & Qu, C. (2017) · International Heart Journal · doi:10.1536/ihj.16-591 · Cited by 9
The Role of Autophagy and Apoptosis in Affected Skin and Lungs in Patients with Systemic Sclerosis
Spasovski, V., Andjelković, M., Parezanovic, M., Komazec, J., Ugrin, M., Klaassen, K., & Stojiljković, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311212 · Cited by 8
Oikawa, Y., Sasaki, N., Niisato, M., Nakamura, Y., & Yamauchi, K. (2016) · Experimental Lung Research · doi:10.3109/01902148.2016.1157226 · Cited by 9
“[26] In our results, ZSTK474 suppressed the vascular remodeling through both inhibiting fibroblast proliferation by PI3K/Akt/mTOR and reducing the collagen production by decreasing TGF-β expression.[27, 28](Figure 5A, B; Figure 7A–D).”
BackgroundMarts, L. T., Guidot, D. M., & Sueblinvong, V. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.03.006 · Cited by 7
AKT regulates IL-1β-induced proliferation and activation of hepatic stellate cells
Yoon, Y., HWANG, S., Saima, F. T., KIM, M. Y., Baik, S. K., & Eom, Y. W. (2023) · Biocell · doi:10.32604/biocell.2023.025365 · Cited by 6
Wang, J., Zhao, X., Feng, W., Li, Y., & Peng, C. Y. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500932 · Cited by 6
小山, 幸., Weber, E. L., & Heinbockel, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910353 · Cited by 6
Venugopal, N., Yeh, J., Kodeboyina, S. K., Lee, T., Sharma, S., Patel, N., & Sharma, A. K. (2019) · Oncology Letters · doi:10.3892/ol.2019.11013 · Cited by 7
“The role of PPARG in lung cancer is unclear, although PPARG has been studied in the context of pulmonary fibrosis, where it was demonstrated to repress myofibroblast differentiation (56).”
BackgroundBagheri, L., Javanbakht, M., Malekian, S., Ghahderijani, B. H., Taghipour, S., Tanha, F. D., Ranjkesh, M. H., Cegolon, L., & Zhao, S. G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177607 · Cited by 5
PPAR-γ Signaling and Common Protective Pathways against Obesity and Alzheimer's Disease
SHARMA, A. K., Devi, S., Mannan, A., Kumar, M., & Singh, T. G. (2024) · Current Signal Transduction Therapy · doi:10.2174/0115743624267214241016103515 · Cited by 4
Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis
Żółkiewicz, J., Stochmal, A., Zaremba, M., Rudnicka, L., & Czuwara, J. (2019) · Advances in Dermatology and Allergology · doi:10.5114/ada.2019.84746 · Cited by 4
“by hypoxia [15] or activated TGF-β signalling [8] or fibrosis is a result of decreased PPAR-γ concentration leading to loss of TGF-β inhibition, fibroblasts to myofibroblasts transition [9] and inflammation.”
BackgroundThe Pro-Fibrotic Response to Lens Injury Is Signaled in a PI3K Isoform-Specific Manner
Menko, A. S., & Walker, J. L. (2022) · Biomolecules · doi:10.3390/biom12091181 · Cited by 4
“In determining whether wound repair is regenerative or fibrotic, the specific roles of PI3Ks also appear to be context specific, their pro-fibrotic signaling function exemplified in studies of idiopathic pulmonary fibrosis in which the transition of lung fibroblasts to myofibroblasts has been linked to activation of P…”
BackgroundLang, N. J., Gote-Schniering, J., Porras-Gonzalez, D., Yang, L., Sadeleer, L. D., Jentzsch, R. C., Shitov, V. A., Zhou, S., Ansari, M., Agami, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.16.524219 · Cited by 4
Macrophages and Pulmonary Fibrosis
Chen, S., Song, X., & Lv, C. (2025) · Current Molecular Medicine · doi:10.2174/0115665240286046240112112310 · Cited by 4
The effect of TGFβRI inhibition on fibroblast heterogeneity in hypertrophic scar 2D in vitro models
Raktoe, R. S., Rietveld, M. H., Out‐Luiting, J. J., Julio, M. K., van Zuijlen, P. P. M., van Doorn, R., & Ghalbzouri, A. E. (2021) · Burns · doi:10.1016/j.burns.2021.01.004 · Cited by 4
Chen, H., Cui, J., Wang, J., Wang, Y., Tong, F., Tian, Y., Gong, Y., Ma, Y., Liu, L., & Zhang, X. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12574 · Cited by 3
Zhang, P., Chen, E., Liu, J., & Xiao, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1599745 · Cited by 2
López‐Isac, E., Acosta‐Herrera, M., & Martin, J. J. (2019) · Rare diseases of the immune system · doi:10.1007/978-3-030-03934-9_2 · Cited by 2
Tissue Distribution and Versatile Functions of PPARs
Youssef, J., & Badr, M. Z. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-420-3_5 · Cited by 5
Fibrotic Signaling in the Lung
Dutta, J. A., Bahudhanapati, H., Tan, J., Goldblum, A., & Kass, D. J. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_4 · Cited by 2
The complexities of cell death mechanisms: a new perspective in systemic sclerosis therapy
Xia, X., Kong, C., Zhao, X., Zhao, K., Shi, N., Jiang, J., & Li, P. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02082-4 · Cited by 1
“The activation of the TGF-β pathway triggers continuous activation of the AKT and ERK1/2 pathways, vital for maintaining hyperphosphorylation in SSc fibroblasts and contributing to their resistance to cell death [31].”
Investigative Approaches to Drug Therapy
Ong, V. H., & Denton, C. P. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5774-0_50 · Cited by 1
[Expression of calponin-1 and its pathogenic role in systemic sclerosis].
Zhao, H., Yang, K., Liu, Q., Hu, J., Wu, W., & Wang, J. (2019) · Europe PMC (PubMed Central) · doi:10.12122/j.issn.1673-4254.2019.03.04 · Cited by 1
“[14]Kulkarni AA, Thatcher TH, Olsen KC, et al.”
BackgroundThe Effects of Poor Maternal Nutrition on Muscle Development in Lambs
Raja, J. (2013) · OpenCommons - UConn (University of Connecticut) · Cited by 1
MOLECULAR STUDIES ON LIM-DOMAIN PROTEIN CRP1
Järvinen, P. P. (2011) · Helda - University of Helsinki Institutional Repository
Zhuang, Y., Li, T., Zhuang, Y., Li, Z., Yang, W., Huang, Q., Li, D., Wu, H., Zhang, G., Yang, T., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.04.012
Investigative Approaches to Drug Therapy
Ong, V. H., & Denton, C. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_42
Endogenous and Exogenous Mechanisms for Healing
Torday, J. S., Blackstone, N. W., & Rehan, V. K. (2018) · doi:10.1002/9781394322190.ch10
Dantas, A. T., de Almeida, A. R., Cordeiro, M. F., de Oliveira, P. S. S., Moura, J. A. D. S., Pereira, M. C., Rêgo, M. J. B. D. M., Gonçalves, R. S. G., Pitta, M. G. D. R., Duarte, Â. L. B. P., et al. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00809-3
Additional file 1 of Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
Li, J.-M., Chang, W.-H., Li, L., Yang, D. C. H., Hsu, S.-W., Kenyon, N. J., & Chen, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26589909
Sutter, J., Geffroy, A., Moretton, A., Græsli, A. R., Kindberg, J., Combaret, L., Lefai, É., Garreau-Balandier, I., Bertile, F., & Vernet, P. (2026) · Scientific Reports · doi:10.1038/s41598-026-43734-y
“However, other studies on pulmonary and cystic fibrosis have reported that AKT activation can promote fibrosis by supporting cell survival, proliferation, migration and ECM production 45,46 , indicating the effects of this pathway are context-dependent.”
Konger, R. L., & Derr-Yellin, E. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094136
Proteomic analysis reveals regional sex differences in healthy and fibrotic human lung
Blomberg, R., Herrera, J., Noelle, H., Mueller, M. C., McCabe, M. C., Schwartz, D. A., & Magin, C. M. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.64898/2026.05.15.725416 · Cited by 1
Jiang, M., Mao, X., & Zhang, L. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103900
Metadata
- Authors
- Kulkarni, A. A., Thatcher, T. H., Olsen, K. C., Maggirwar, S. B., Phipps, R. P., & Sime, P. J.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- Sime, Patricia J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-06
- Volume
- 6
- Issue
- 1
- Pages
- e15909
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3017065
- OpenAlex
- W1991127474
- Cited by
- 189
- References
- 60
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 8 · 2023: 13 · 2022: 11 · 2021: 12 · 2020: 7 · 2019: 22 · 2018: 10 · 2017: 16 · 2016: 10 · 2015: 16 · 2014: 10 · 2013: 9 · 2012: 22
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Rochester
- National Institutes of Health (ES01247, ES-07026)
- National Heart, Lung, and Blood Institute (R03HL095402, F30HL097596, T32HL066988, HL075432-04S2, HL095402-02, HL075432-04S1, R01HL075432, HL075432)
- National Institute of Environmental Health Sciences (P30ES001247, T32ES007026)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- PPARγ ligands, TGF-beta signaling, myofibroblast differentiation, pulmonary fibrosis, idiopathic pulmonary fibrosis, PI3K/Akt signaling, Akt phosphorylation, CDDO, prostaglandin A1, FAK phosphorylation, lung fibroblasts
- MeSH terms
- Cell Differentiation, Fibrosis, Humans, Ligands, Phosphorylation, Signal Transduction, Transforming Growth Factor beta, PPAR gamma, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.